Longer‐acting clotting factor concentrates for hemophilia
Author:
- 1 June 2015
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 13 (S1) , S167-S175
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- PROLONG-9FP clinical development program – phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)Thrombosis Research, 2013
- Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIIIThrombosis Research, 2013
- Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or bloodThrombosis and Haemostasis, 2013
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- The tertiary structure and domain organization of coagulation factor VIIIBlood, 2008
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007